Drug
Nonoxynol-9
Nonoxynol-9 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Study of the Effects of Advantage 24 on the Rectum
NCT00000929
completedphase_3
A Study of Nonoxynol-9 (N-9) and HIV Infection
NCT00000926
completedearly_phase_1
A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides
NCT00389311
completedphase_2
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
NCT01593124
Clinical Trials (4)
Showing 4 of 4 trials
NCT00000929Phase 1
A Study of the Effects of Advantage 24 on the Rectum
NCT00000926Phase 3
A Study of Nonoxynol-9 (N-9) and HIV Infection
NCT00389311Early Phase 1
A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides
NCT01593124Phase 2
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4